#### 1 Reduced Bacille Calmette-Guérin-specific IgG titres among babies born to mothers with

### 2 Active Tuberculosis Disease in Uganda

- 3 Authors
- 4 Diana Sitenda<sup>\*1,2,3</sup>, Phillip Ssekamatte<sup>1,2,7</sup>, Rose Nakavuma<sup>2</sup>, Andrew Peter Kyazze<sup>2,8</sup>, Felix
- 5 Bongomin<sup>4</sup>, Joseph Baluku<sup>7</sup>, Rose Nabatanzi<sup>1</sup>, Davis Kibirige<sup>2,6</sup>, Annette Nakimuli<sup>5</sup>, Stephen
- 6  $\operatorname{Cose}^7$ , Irene Andia-Biraro<sup>2,7,8</sup>.

### 7 Affiliations

- 8 1. Department of Immunology and Molecular Biology, School of Biomedical Sciences,
- 9 College of Health Sciences, Makerere University, Kampala, Uganda.

10 2. Tuberculosis and comorbidities research consortium, Kampala, Uganda.

- Health Professions Education and Training for Strengthening the Health System and
   Services, Kampala, Uganda.
- 4. Department of Medical Microbiology and Immunology, Gulu University (GU), Gulu,
   Uganda.
- 5. Department of Obstetrics and Gynaecology, School of Medicine, College of Health
   Sciences, Makerere University, Kampala, Uganda.
- 17 6. Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala, Uganda
- 7. Medical Research Council/ Uganda Virus Research Institute and London School of
  Hygiene and Tropical Medicine, Entebbe, Uganda.
- 8. Department of Internal Medicine, School of Medicine, College of Health Sciences,
   Makerere University, Kampala, Uganda.
- 22 \*Correspondence
- 23 Corresponding Author: Ms Diana Sitenda

24 Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere

#### 25 University, Kampala, Uganda.Email: dianasitenda@gmail.com

#### 26 Abstract (284)

**Background:** Babies born to mothers with active tuberculosis disease (ATB) are at risk of poor clinical outcomes such as low birth weight and perinatal mortality. However, little is known about the influence of maternal ATB exposure on their vaccine responses during infancy. The study aimed to explore how maternal ATB affects infants' vaccine responses, hypothesising reduced responses to BCG and other infant vaccines.

Methods: This was a case-control study with a longitudinal component of babies born to mothers with bacteriologically confirmed ATB (cases) and babies born to mothers without ATB (controls) carried out between September 2021 and June 2022. Quantitative BCG, diphtheria, tetanus, and measles-specific IgG ELISA assays were performed on infant plasma harvested from lithium-heparin blood collected on first encounter after birth (0), at 3, 6, and 9 months. We used prism v10.1.2, Mixed-effects modelling, and Tukey's multiple comparison testing to determine mean differences (MD) between the cases and controls at all time points.

Results: Infants cases had reduced IgG titres to BCG at baseline compared to the controls 39 40 (p=0.04), with a mean of 125.8/141.1 IU/mL, respectively. This difference was, however, not 41 sustained at the other time points. Similarly, we demonstrated strong trends of reduced responses 42 to tetanus, diphtheria, and measles vaccines among infant cases at baseline and three-month time 43 points and weakly at months six and nine. The mean titres for tetanus at baseline and 3 months for cases versus controls are 1.744/2.917 IU/mL and 1.716/2.344 IU/mL (p<0.0001/0.018), 44 respectively. The mean titres for diphtheria at 3 months were 0.022/0.075 IU/mL (p=0.006), 45 46 respectively.

47	Conclusion: We have demonstrated that maternal TB disease influences vaccine responses to
48	BCG and other infant vaccines. This has implications for increased risk of childhood TB and
49	other preventable diseases.
50	Keywords: Active tuberculosis, Mothers, Infants, Vaccine response.
51	Funding: This study was funded by the CRCK African Network (CAN) through the Francis

52 Crick Institute, United Kingdom, and Health Professions Education and Training for

53 Strengthening the Health System (HEPI-SHSSU) and Services in Uganda.

## 54 Introduction

55 The incidence of Tuberculosis (TB) disease among people aged below 30 years of age has 56 increased, hence increasing the number of childbearing women contracting the disease (1). The 57 TB burden in pregnancy globally is estimated to be 216,500 cases annually, with an increased threefold risk of TB in this population (2). Mother-to-child transmission of TB may occur in 58 59 utero through hematogenous spread via the umbilical vein and aspiration or swallowing of 60 infected amniotic fluid (3, 4). TB disease in pregnancy leads to poor maternal and foetal outcomes such as preterm birth, low birth weight (5), perinatal death, congenital anomalies, 61 62 small for gestational age, foetal distress, low Apgar scores, and rare congenital tuberculosis (6).

63 There is limited data on the immune responses to BCG and other vaccines of infants born to mothers with active TB (ATB). Vaccination with BCG has been reported to be associated with 64 65 reduced infant mortality (7, 8) although it still remains unclear whether this is true to all populations including babies born to mothers with active tuberculosis. A study by Lubyayi et al., 66 2020 revealed that maternal Latent TB status does not affect the infants' response to BCG-67 68 vaccine (9). On the other hand, Mawa et al., 2015 reported a decrease in PPD-specific responses 69 among infants born to mothers with latent tuberculosis infection at one week and six- weeks 70 following vaccination with BCG compared to the control group (10). Both studies explored the impact of maternal latent TB on infant vaccine responses; however, in this study, we assessed 71 vaccine responses among infants born to active TB mothers and compared them with babies born 72 73 to TB-uninfected mothers. We found it important also to determine if exposure to TB disease 74 influenced the other infant vaccines to pave the way for possible public health-related 75 interventions, given that HIV alone has been implicated in causing a reduced response to 76 vaccines among infants (11).

- 77 This study determined the IgG titer responses to Bacille Calmette-Guérin (BCG), diphtheria,
- tetanus, and measles vaccines in babies born to mothers with and without active TB disease at
- 79 baseline, three, six, and nine months of follow-up.

## 80 Materials and Methods

#### 81 Study design and population

This was a case-control study with a longitudinal component. The study enrolled 35 women with 82 83 bacteriologically confirmed active TB as cases and 33 women without TB as controls matched 84 for maternal and gestational age from antenatal (ANC) and postnatal (PNC) clinics at three major health facilities in Kampala, Uganda: Kasangati Health Center IV, Kisenvi Health Center IV, and 85 Kawempe National Referral Hospital. However, we considered 25 cases (babies born to mothers 86 87 with active tuberculosis disease) and 25 controls (babies born to mothers without active 88 tuberculosis disease) in our experiments, whose numbers also dropped in successive follow-up months. Upon delivery, babies were assented to, enrolled in the study, and were followed up for 89 nine months. These babies donated up to six milliliters of blood in lithium-heparin tubes at 90 91 different time points, from which plasma was harvested and stored at  $-20\Box$  in a freezer at the Immunology laboratory of Makerere University College of Health Sciences (MakCHS). The 92 93 baseline visit (V0) marked the visit of the first encounter with infants aged less than a month 94 (cases, n=19 versus controls, n=15). The V1 marked a visit at three months (cases n=15 versus controls n=14), V2 at six months (cases n=12 versus controls n=8), and V3 at 9 months (cases 95 n=8 versus controls n=4). Vaccine schedules included BCG at birth; pentavalent tetanus-96 diphtheria-pertusis-hepatitis B-haemophilus influence type B (DPT-HEPB-HIB1) at 6, 10, 14 97 weeks; and measles at nine months. 98

#### 99 Laboratory methods

Heparin blood was layered over Ficoll-paque in a ratio of 1:2 under a biosafety cabinet in a 15ml
Falcon tube. This was spun in a centrifuge at 1800rpm for 30 minutes to separate plasma and
PBMCs from red blood cells. Plasma was harvested using a pipette and was stored at -20°C

103 freezer. All assays for each vaccine were optimised to achieve a suitable dilution factor. 104 Archived available plasma samples were retrieved from a  $-20\Box C$  freezer and transferred to the fridge at the temperature of  $4\Box$  overnight. They were then retrieved from the refrigerator and 105 106 that the ELISA kits at room temperature  $(25\Box)$  for 1 hour. Plasma samples were vortexed to achieve uniform mixing, and 50µl were loaded into designated wells, in addition to 107 standards and blanks, of the 96-well ELISA plates. The human IgG-specific ELISA assays were 108 performed to determine plasma IgG titres of BCG, Diphtheria-Tetanus, and Measles vaccine 109 responses using the human BCG (Cat No. MBS702330), diphtheria (Cat No. MBS495632), 110 111 tetanus (Cat No. MBS9907877) and measles (Cat No. MBS283708) IgG ELISA kits following the manufacturer's instructions. The absorbance at 450/620 nm was measured using the Gen 5 112 software version 2.71.2 for the ELISA reader (Synergy LX multimode reader). Detailed 113 procedures are available in the supplementary materials. 114

### 115 **Data analysis and management**

116 Optical densities (ODs) from the ELISAs were converted to concentrations using the Gen 5 software version 2.71.2 and then exported to Excel. Using Excel, the data was cleaned and 117 grouped as cases versus controls at baseline, 3, 6, and 9 months. Data was statistically analysed 118 119 in GraphPad Prism v9.5.1 using the Mixed model effect analysis with Tukey's multiple comparisons test. Means, mean difference (MD), and standard error of difference (SE) for both 120 cases and controls were computed at all time points. A simple linear regression analysis was 121 performed on the relationship between birth weight, haemoglobin, and vaccine responses at all 122 time points. The Mann-Whitney U-test was used to determine statistical differences in baby 123 124 weights, age, and the mother's haemoglobin concentrations among both cases and controls. The

chi-square test was also used to determine statistical differences in the gender of babies, their
postnatal versus antenatal enrolments, and their maternal HIV status.

### 127 Ethical considerations

This study received ethical approval from the School of Medicine Research and Ethics Committee (SOMREC reference number SOM 2020-11); the School of Biomedical Sciences (SOBSREC reference number SBS-2022-226) at Makerere University; and the Uganda National Council for Science and Technology (UNCST registration number HS1396ES). The mothers provided written informed consent and assent for their babies to participate in the study.

## 133 **Results**

## 134 Characteristics of the study participants

Babies born to mothers with ATB had lower birth weights than those born to mothers without ATB (p=0.03), as shown in Table 1. In addition, case mothers had lower haemoglobin concentrations compared to controls. The median (g/dl) and IQR cases versus controls are 11.2 (10.0-11.9)/ 13.0 (10.7-13.8) (p=0.033). Other characteristics such as age, gender, maternal HIV status, and postnatal versus antenatal babies were found to be similar for both cases and controls.

### 140 BCG-specific IgG responses

The IgG titres were determined in plasma samples of the case babies versus the control babies. The samples were collected at V0, V1, V2, and V3, and the titres were compared at all time points. The IgG titres were strongly decreased in cases versus controls (p=0.032) at V0. The mean for cases versus controls (IU/mL), mean difference (MD) 95% confidence interval (CI), Pvalue, and Standard Error (SE)] are shown in Table 2. This was followed by a gradual reduction

- 146 at the rest of the time points: 3, 6, and 9 months (p=0.574/0.626/0.717), respectively. These
- 147 differences were, however, not supported, as demonstrated in Figure 1 (A and B).
- 148 IgG vaccine responses to other vaccines
- 149 **Tetanus-specific IgG responses**
- Baby cases had slightly lower IgG responses to tetanus at baseline compared to the controls
- 151 (p<0.0001)
- and this was followed by a significant decrease at 3 months (p=0.018). The mean (IU/mL), mean
- difference (MD), 95% confidence interval (CI), P-value, and Standard Error (SE) are shown in

Table 2. The trends showed a steep reduction in the responses among controls; however, the tetanus titres among cases increased gently up to 9 months, slightly surpassing the controls observed to fairly rebound at 9 months, as shown in Figure 2(A and B).

## 157 Diphtheria-specific IgG responses

Cases had strongly reduced IgG responses at 3 months of follow-up (p=0.0059) compared to controls. The mean (IU/mL), mean difference (MD) 95% confidence interval (CI), P-value, and Standard Error (SE) are shown in Table 2. A sharp increase followed this in titres, which peaked at 6 months and then dropped at 9 months for controls. On the other hand, the responses for cases are steadily maintained from baseline up to the end of follow-up, as shown in Figure 2(C and D). At months 6 and 9, the p values were p=0.8563 and 0.8589, respectively. No difference was observed in the response to diphtheria at baseline (p=0.392).

## 165 Measles-specific IgG responses

166 The trends showed that cases had a slightly higher response at all time points than controls, with 167 the highest response shown at month 9. On the contrary, controls show waning titres between 6, 168 months 6 and 9. At baseline, 3, and months, the 9 р values were:

p=0.7402/0.9339/0.4409/0.5155, respectively. These differences were, however, not statistically
supported, as shown by Figure 2(E and F). The mean (IU/mL), mean difference (MD) 95%
confidence interval (CI), P-value, and Standard Error (SE) are shown in Table 2.

172 Impact of birth weight on vaccine responses

173 In this study, we further grouped cases and controls as either normal or low weights (kgs) based 174 on the World Health Organisation's guidelines, and babies with a weight lower than 2.5 kgs were 175 considered low weight. Normal weight ranged between 2.5 and 4.0 kgs. BCG and tetanusspecific IgG titres for normal weight were lower among cases than controls. However, there was 176 no difference in diphtheria and measles vaccine responses between low and normal-weight 177 178 babies, as shown in Figure 3 (A, B, C, and D). A comparison of the vaccine responses to BCG, 179 tetanus, diphtheria, and measles vaccines and normal birthweight revealed that cases with normal 180 weight had low responses to BCG and tetanus vaccines. No differences were observed among low-weight babies and measles and diphtheria responses. For normal weight (cases versus 181 182 controls), BCG, p=0.007; tetanus, p=0.004; DPT, p=0.093; measles, p=0.055. The regression 183 analysis also revealed that weight slightly affected BCG responses (p=0.06); however, this was 184 not statistically supported.

#### 185 **Discussion**

Pregnancy modulates the immune response towards Th2-type response (12) increasing susceptibility to intracellular pathogens, including TB (13). This study demonstrated that babies born to mothers with ATB have reduced BCG-specific IgG titres at baseline. Maternal tuberculosis disease potentially leads to the transfer of tuberculosis antigens to the foetus, thereby resulting in an altered priming of the immune response (14). The observed reduced BCG responses at baseline could, therefore, result in anergy induced by maternal antibodies; however,

192 this remains to be explored. The responses remained relatively stable over time. The results 193 further show that cases had slightly reduced responses at six months for BCG responses, unlike 194 for Measles. These results contradict what Edwards, 2015 (15) reported: measles vaccine 195 responses were reduced at six months, possibly due to passive maternal antibodies. On the other hand, Nabunya et., 2020 reported that about 36% of infants are not breast fed beyond six months, 196 197 in Uganda (16). This implies that the transfer of the antibodies is reduced. Our results suggest the 198 insufficiency in responses to the BCG vaccine due to TB exposure. These findings show that maternal TB may impair the infants' immune responses to the BCG vaccine. We suggest that 199 200 careful attention is taken to ensure that the infants exposed to TB can develop protective 201 immunity following vaccination to protect infants from early-life infections and deaths from active TB. 202

203 In addition to BCG, the study reported a reduction in Diphtheria-specific IgG-specific titres 204 among cases at three months. Tetanus-specific IgG-specific vaccine responses were reduced at 205 baseline and three months among cases compared to the controls. This data highlights that 206 maternal TB disease indeed influences responses to vaccines among infants, and care should be 207 taken to ensure that these exposed infants achieve protective immunity following vaccination. 208 This will be aimed towards averting early-life infections and, consequently, potential infant 209 deaths attributable to active TB. DPT and measles responses are seen to rebound after three 210 months, shooting higher among cases than the controls at 6 and 9 months; however, the 211 differences in fluctuations are not significant. On the other hand, Tetanus responses for cases are 212 relatively stable over time, indicating minimal responsiveness to the vaccine.

The observed decrease in the IgG-specific diphtheria vaccine responses is consistent with findings from similar studies. Abu-Raya et al., 2021 found lower IgG levels in children whose

mothers had received the Tdap vaccine (17). Due to the impact of TB in pregnancy, including the low birth weight of babies, vaccination tends to be delayed. When administered, low vaccine responses are more likely to occur (18) predisposing infants to developing vaccine-preventable diseases and experiencing severe or fatal disease outcomes. It has also been demonstrated that maternal *Mtb* infection during pregnancy raises levels of immune-regulatory cytokines (19), which inhibit the infant's immunological response to vaccinations.

The current study also reports decreased Tetanus-specific IgG vaccine titres among cases. 221 222 Because the vaccine is administered at six weeks (20), there could have been delayed priming of B cells. In addition, since pregnant women are vaccinated with Tetanus toxoid (21), the maternal 223 224 IgG that crosses the placenta is likely to induce anergy to the infant's immune system, thereby 225 causing a dampened immune response. These findings highlight the need for improved vaccine 226 strategies for infants exposed to TB and a better understanding of vaccine failures in certain 227 populations. The effects of TB exposure are also seen with other vaccines like Diphtheria and 228 Tetanus. With vaccine failure in a certain group of people, efforts need to be taken to identify 229 more shortfalls of the existing vaccines and pave the way for effective vaccines possibly tailored 230 to populations. This will enormously contribute to the End TB strategy.

This study further highlights the impact of maternal TB on the birth outcomes of babies, especially low birth weight. Similar results were reported elsewhere (22, 23), affirming this outcome. Vaccination delays associated with low birth weight further hamper the health outcomes of these babies, contributing to lower responses to vaccines and increased vulnerability to infections (24). We postulate that the effects of TB exposure are not only observed with low birth weight. Therefore, when assessing for TB exposure aftereffects, babies with normal weight should not be overlooked. Moreover, the regression analysis revealed that the weight of the

babies slightly affected BCG-specific IgG responses, as shown in supplementary figure S1A. Our results also revealed that the mothers to our cases had low haemoglobin concentrations compared to the mothers of the controls. Low haemoglobin during pregnancy is associated with poor neonatal outcomes not limited to preterm births and very low birthweights (25). However, the babies' responses were not affected by their haemoglobin concentrations following the regression analysis, as shown in Supplementary Figure S1B. These findings show an increased risk for these mothers, especially resulting in preterm babies and low-weight babies.

## 245 **Strengths and limitations**

246 In this study, baby case samples were matched with controls regarding age and gender to control 247 for confounder biases. We report that the study had some limitations. The ATB yield was low, which affected the number of participants studied. However, we were able to demonstrate a 248 249 statistically supported difference. Some of our participants were enrolled during puerperium, so 250 the babies received the initial vaccines before enrolment. This limited our understanding of the 251 initial status of these babies before vaccination. Also, data on mothers' vaccination status against 252 tetanus during pregnancy was not collected, and we can only anticipate that since it is part of 253 routine antenatal care, they all received this vaccine. We anticipate that this could have further 254 dampened immune responses to the vaccine among cases.

#### 255 Conclusion

Babies born to mothers with active TB disease: (i) Had low birth weights, (ii) Presented with reduced vaccine-specific IgG responses for BCG and the other infant vaccines in general but markedly at baseline. This could be resulting from persistent *Mycobacterial tuberculosis* antigenemia. We speculate a similar scenario to the *DoHAD* theory. We propose a larger prospective study with longer follow-ups to explore outcomes of vaccination and TB disease

261 risk. This would also answer whether the suppressed response to the vaccine among exposed 262 infants is due to other factors such as the participant's household or environment and nutrition, in 263 addition to revealing whether the responses improve or completely diminish over time. A study 264 on determining the quality of antibodies from active TB mothers, which would look at antibody 265 affinity and avidity to compare these between cases and controls, is necessary. Finally, looking at 266 the transcriptomic changes in the blood of these infants exposed to TB would be insightful. This 267 would inform some of the highly expressed biomarkers potentially used to diagnose childhood 268 TB.

#### 269 **References**

Perumal R, Naidoo K, Padayatchi N. TB epidemiology: where are the young women?
 Know your tuberculosis epidemic, know your response. BMC Public Health. 2018;18(1):417.

272 2. K JS, A B, G KH, S MG. Tuberculosis in pregnant women and neonates: A meta-review
273 of current evidence. Paediatr Respir Rev. 2020;36:27-32.

Lee JS, Lim CH, Kim E, Lim H, Lee Y, Choung JT, et al. Congenital miliary tuberculosis
 in an 18-day-old boy. Korean J Pediatr. 2016;59(Suppl 1):S64-s7.

Samedi V, Field SK, Al Awad E, Ratcliffe G, Yusuf K. Congenital tuberculosis in an
 extremely preterm infant conceived after in vitro fertilization: case report. BMC Pregnancy and
 Childbirth. 2017;17(1):66.

Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol.
2020;135(6):1444-53.

Hui SYA, Lao TT. Tuberculosis in pregnancy. Best Pract Res Clin Obstet Gynaecol.
 2022;85(Pt A):34-44.

7. Thysen SM, Benn CS, Gomes VF, Rudolf F, Wejse C, Roth A, et al. Neonatal BCG
vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort
study. BMJ Open. 2020;10(2):e035595.

8. Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskär T, Sommerfelt H, for the P-EBFSG.

287 Child survival and BCG vaccination: a community based prospective cohort study in Uganda.

288 BMC Public Health. 2015;15(1):175.

Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, Serubanja J, et al.
 Maternal Latent Mycobacterium tuberculosis Does Not Affect the Infant Immune Response
 Following BCG at Birth: An Observational Longitudinal Study in Uganda. Front Immunol.
 2020;11:929.

10. Mawa PA, Nkurunungi G, Egesa M, Webb EL, Smith SG, Kizindo R, et al. The impact
of maternal infection with Mycobacterium tuberculosis on the infant response to bacille
Calmette-Guerin immunization. Philos Trans R Soc Lond B Biol Sci. 2015;370(1671).

11. Mansoor N, Scriba TJ, de Kock M, Tameris M, Abel B, Keyser A, et al. HIV-1 infection
in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. J
Infect Dis. 2009;199(7):982-90.

Sykes L, MacIntyre DA, Yap XJ, Ponnampalam S, Teoh TG, Bennett PR. Changes in the
Th1:Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentenone
prostaglandin 15-deoxy-Δ(12,14)-prostaglandin J2. Mediators Inflamm. 2012;2012:416739.

302 13. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal Immunological
303 Adaptation During Normal Pregnancy. Front Immunol. 2020;11:575197.

14. Langel SN, Blasi M, Permar SR. Maternal immune protection against infectious diseases.

305 Cell Host & Microbe. 2022;30(5):660-74.

Edwards KM. Maternal antibodies and infant immune responses to vaccines. Vaccine.
2015;33(47):6469-72.

- 16. Nabunya P, Mubeezi R, Awor P. Prevalence of exclusive breastfeeding among mothers
  in the informal sector, Kampala Uganda. PLoS One. 2020;15(9):e0239062.
- 17. Abu-Raya B, Maertens K, Munoz FM, Zimmermann P, Curtis N, Halperin SA, et al. The
- 311 Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant
- Antibody Responses: Individual-Participant Data Meta-Analysis. Front Immunol.
  2021;12:689394.
- 18. Soans S, Mihalyi A, Berlaimont V, Kolhapure S, Dash R, Agrawal A. Vaccination in
  preterm and low birth weight infants in India. Hum Vaccin Immunother. 2022;18(1):1-12.
- 316 19. Manjeese W, Mvubu NE, Steyn AJC, Mpofana T. Mycobacterium tuberculosis-Induced

317 Maternal Immune Activation Promotes Autism-Like Phenotype in Infected Mice Offspring. Int J

- Environ Res Public Health. 2021;18(9).
- 319 20. Keja K, Chan C, Hayden G, Henderson RH. Expanded programme on immunization.
  320 World Health Stat Q. 1988;41(2):59-63.
- 321 21. Gupta SD, Keyl PM. Effectiveness of prenatal tetanus toxoid immunization against
   322 neonatal tetanus in a rural area in India. Pediatr Infect Dis J. 1998;17(4):316-21.
- 22. LaCourse SM, Greene SA, Dawson-Hahn EE, Hawes SE. Risk of Adverse Infant
  Outcomes Associated with Maternal Tuberculosis in a Low Burden Setting: A Population-Based
  Retrospective Cohort Study. Infect Dis Obstet Gynecol. 2016;2016:6413713.
- 326 23. Yadav V, Sharma JB, Kriplani A, Bhatla N, Kachhawa G, Mahey R, et al. Obstetrics
  327 outcome in pulmonary tuberculosis. Indian Journal of Tuberculosis. 2022;69(3):305-10.

Banu EA, Nechita A, Elkan-Cojocaru EM, Baciu G, Manole A, Chelaru L. Risk of
tuberculosis in low birth weight children from East Romania. Arch Med Sci. 2020;16(1):162-6.

Zhang Q, Lu X-M, Zhang M, Yang C-Y, Lv S-Y, Li S-F, et al. Adverse effects of iron
deficiency anemia on pregnancy outcome and offspring development and intervention of three

iron supplements. Scientific Reports. 2021;11(1):1347.

#### 333 Author contributions

334 DS performed laboratory experiments, analysed data, and drafted the manuscript. IAB, AN, SC,

RN, FB, JBB, PS, APK, DK, and NR participated in the concept development and reviewed the

- manuscript. PS developed the experimental protocols that followed the experiment and offered
- technical laboratory training to perform the experiments. IAB sourced funding for the research.

## **Declaration of conflict of interest**

339 The authors declared no conflict of interest.

340 Data availability

341 The authors will make raw data that guided these conclusions available upon request.

## 342 Acknowledgement

A vote of special thanks goes to the Tuberculosis and Comorbidities Research Consortium's field team for data collection. We thank the study participants and the health facility administrators for their engagement in this study. This work was supported by the Crick African Network, which receives its funding from the UK's Global Challenges Research Fund (MR/P028071/1), and by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC1001647), the UK Medical Research Council (FC1001647), and the Wellcome Trust (FC1001647). We also acknowledge HEPI-SHSS for offering a research contribution to

- the laboratory work. This work was presented at conferences and an abstract of this work was
- published as a conference paper in BMJ, by the EDCTP Forum, 2023.

# 352 Tables

## 353 **Table 1 shows baseline participant characteristics**

Babies	Cases (n=25)	Controls (n=25)	P value
*Weight (Kgs)	3.0 (2.1 - 3.2)	3.4 (2.7 - 4.4)	0.03
[median (IQR)]			
Age (weeks)	7 (2-12)	12 (1-16)	0.45
[(median (IQR)]			
Sex (male)	8	8	>0.99
(female)	12	12	
HIV status (positive)	7	8	0.47
(negative)	18	13	
Antenatal care (ANC)	6	4	0.63
Postnatal care (PNC)	19	18	

\*Means a p-value less than 0.05. Missing values for weight, age, sex, haemoglobin concentration, HIV status, and Antenatal versus postnatal care are 11, 12, 10, 10, 4, and 3, respectively.

# 358 Table 2: Vaccine responses among cases and control at the different follow-up time points

Type of	Mean	Mean Difference		SE of difference	P-Value
Vaccine	(IU/mL)	(MD)	95% CI		
BCG					
Baseline			· · · · · · · · · · · · · · · · · · ·		· · ·
(V0)					
Cases	125.8	-15.37	-29 30 to -1 449	6.727	0.032
Controls	141.1		29.30 10 1.119		
Month 3					
(V1)					
Cases	122.6	-5.605	-25.77 to 14.56	9.862	0.574
Controls	128.2				
Month 6					
(V2)					
Cases	113.6	-6.531	-34 57 to 21 50	13.130	0.626
Controls	120.1		54.57 to 21.50		
Month 9					
(V3)					
Cases	116.8	17.37	145.1 to 170.0	42.220	0.717
Controls	99.42		-145.1 10 179.9		

Tetanus					
V0					
Cases	1.744	-1.173	-1.647 to -	0.226	<0.0001
Controls	2.917		0.6989		
V1					
Cases	1.716	-0.6286	-1.139 to -	0.248	0.018
Controls	2.344		0.1186		
V2					
Cases	1.595	-2.645	5 800 to 0 5080	1.437	0.098
Controls	4.240		-3.890 10 0.3989		
V3					
Cases	1.713	-0.5535	-10 88 to 9 778	0.912	0.649
Controls	2.267		-10.00 10 9.770		
Diphtheri	a				
V0					
Cases	0.042	-0.01935	-0.066 to 0.027	0.022	0.392
Controls	0.062		-0.000 to 0.027		
V1					
Cases	0.022	-0.05215	-0.08795 to -	0.017	0.0059
Controls	0.075		0.01635		
V2					
Cases	0.045	0.004833	-0.05016 to	0.026	0.8563

Controls	0.040		0.05983		
V3					
Cases	0.063	0.008933	-0.1102 to	0.048	0.8589
Controls	0.054		0.1281		
Measles					
V0					
Cases	1.759	0.1600	0.9246 to 1.145	0.4768	0.7402
Controls	1.599		-0.8240 to 1.143		
V1					
Cases	1.582	-0.04220	1.000 / 0.0020	0.5047	0.9339
Controls	1.624		-1.008 to 0.9850		
V2					
Cases	2.702	0.6660	1 115 4 0 447	0.8439	0.4409
Controls	2.036		-1.115 to 2.447		
V3					
Cases	2.990	1.230	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1.757	0.5155
Controls	1.760		-3.300 to 5.759		

### 360 Legends

366

Figure 1(A and B). Plasma was used to perform ELISA using the Human BCG antibody ELISA kit. Two replicates of each sample were used for both case and control samples. The number of samples (n) for cases and controls at V0 was 19/15; at V1, n= 15/15; at V2, n=12/8; and at V3, n=8/3 respectively. Statistical differences were determined using mixed effects analysis and Tukey's multiple comparison tests. Statistical significance was determined at p<0.05 and a 95%

confidence level. \* Implies a p-value less than 0.05.

Figure 2 (A and B). Stored plasma was used to perform ELISA using the Human Tetanus 367 Toxoid Antibody IgG (TT-IgG) ELISA Kit. The number of cases versus controls used at each 368 visit was V0=18/17, V1=15/11, V2=11/10, and V3=9/4, respectively. Statistical differences were 369 determined using mixed effects analysis and Tukey's multiple comparison tests. Statistical 370 significance was determined at p<0.05 and a 95% confidence level. \* and \*\*\*\* imply a p-value 371 less than 0.05 and 0.0001, respectively. Figure 2 (C and D). The plasma was then used to 372 perform ELISA using the Corynebacterium diphtheriae toxin IgG ELISA kit. The number of 373 374 cases versus controls at V0=20/14, V1=15/15, V2=13/7, and V3=8/4, respectively. Statistical differences were determined using mixed effects analysis and Tukey's multiple comparison tests. 375 Statistical significance was determined at p<0.05 and a 95% confidence level. \*\* indicate a p-376 value less than 0.01. Figure 2 (E and F). Plasma was used to perform ELISA using the Human 377 378 Measles virus IgG antibody (MV-Ab-IgG) ELISA Kit. The number of cases versus controls used 379 at V0=20/16, V1=18/12, V2=11/9, and V3=8/5, respectively. Statistical differences were determined using mixed effects analysis and Tukey's multiple comparison tests. Statistical 380 381 significance was determined at p<0.05 and a 95% confidence level.

Figure 3 (A, B, C, D). This figure shows a sub-analysis of IgG vaccine-specific responses for babies of low and normal weights. Mann-Whitney U test was used to determine the statistical differences. Data were expressed as median and interquartile ranges. \*\* indicate a p-value less than 0.01.





